Condition: Alcohol Use Disorder · Sponsor: Clearmind Medicine Inc.
The primary objective of this study is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in Healthy Volunteers (HV) and Subjects with Alcohol Use Disorder (AUD). The secondary objective of this study is to preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in subjects with moderate to severe AUD.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Connecticut Mental Health Center | New Haven, Connecticut, United States | Recruiting |
| Johns Hopkins Bayview Medical Center | Baltimore, Maryland, United States | Recruiting |
| Hadassah Medical Center | Jerusalem, Israel | Recruiting |
| Tel-Aviv Sourasky Medical Center (TASMC) | Tel Aviv, Israel | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05913752